Pharma Co. Reports Q1 Results and Advances Ersodetug Toward 2027 BLA Filing

Important Disclosures:

1. Cori Fisher wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee. 
2. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
3. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

Ownership percentages, named holders, share count, market capitalization, and the 52-week range for Rezolute were compiled from company public filings and investor materials, exchange notices, insider-trade reports (SEDI / equivalent), and third-party data providers. Figures are as of 2026-11-06 unless a source was dated earlier. Pie slices are normalized to 100% of basic shares outstanding; retail is the residual after disclosed institutions, management, insiders, and strategic holders. Warrant terms are current outstanding series only. Restructures are historical consolidations, splits, and symbol or name changes. Insider buying and selling covers open-market trades from the prior six months through 2026-11-06 and excludes option exercises. These are public-source estimates and can differ from a later official register.

Rezolute Inc. (RZLT:NASDAQ), a late-stage ultra-rare metabolic disease company focused on treating refractory hypoglycemia caused by hyperinsulinism (HI), reported Q1 fiscal 2027 financial results and provided a clinical and regulatory update on November 5, 2026.

The company also reported completed enrollment in its Phase 3 tumor HI study, an updated regulatory pathway for its congenital HI program, and plans to pursue potential Biologics License Application (BLA) submissions in 2027.

Key Investor Takeaways

• Rezolute completed enrollment in its Phase 3 upLIFT study of ersodetug for tumor-induced hyperinsulinism, with topline results expected by mid-December 2026.
• Seven of the first eight upLIFT participants met the primary endpoint responder criterion and achieved complete discontinuation of intravenous glucose.
• The FDA recommended that Rezolute request a pre-BLA meeting for its congenital HI program following its review of additional clinical data, despite the Phase 3 sunRIZE study missing its primary endpoint.
• Rezolute reported US$90 million in cash, cash equivalents, and marketable securities as of September 30, 2026, and filed a US$400 million mixed-securities shelf registration.
• Management identified a potential US$5 billion combined market opportunity for ersodetug across its HI indications and is targeting potential BLA submissions in 2027.

Q1 Fiscal 2027 Results and Clinical Updates

Rezolute reported a net loss of US$18.5 million for Q1 of fiscal 2027, compared with a net loss of US$18.2 million during the same period in fiscal 2026. Research and development (R&D) expenses totaled US$12.8 million, down from US$13.1 million a year earlier, while general and administrative expenses were US$6.6 million, compared with US$6.7 million in the prior-year period. The company attributed the decrease in R&D expenses primarily to lower manufacturing costs for ersodetug and patient affairs costs, partially offset by higher employee-related stock-based compensation expenses. The company ended September 30, 2026, with US$90.0 million in cash, cash equivalents, and marketable securities, compared with US$107.8 million at June 30, 2026.

In other news, Rezolute completed enrollment in its Phase 3 upLIFT study evaluating ersodetug for tumor-induced hyperinsulinism. The open-label, single-arm study enrolled up to 16 hospitalized participants, with topline results expected by mid-December 2026.  Earlier results from the first half of the study showed that seven of eight participants met the primary endpoint responder criterion. Each of those seven participants also achieved complete discontinuation of intravenous glucose following treatment with ersodetug. The eighth participant discontinued the study drug shortly after enrollment to pursue hospice care at home and died one week later due to cancer progression. Rezolute classified this participant as a non-responder for the primary endpoint. 

The company also reported that ersodetug had been well-tolerated in the study, with no drug-related safety findings reported to date. The upcoming topline results will provide a more complete assessment of the treatment's performance in the study population. 

Rezolute also provided an update on its congenital HI program following additional data review by the U.S. Food and Drug Administration (FDA). In October 2026, the FDA recommended that the company request a Type B pre-BLA meeting as a precursor to a potential Biologics License Application (BLA) submission. The meeting had not yet taken place as of November 5, with Rezolute expecting to request it during the first half of 2027.

The regulatory development follows the Phase 3 sunRIZE study, which evaluated ersodetug in patients with congenital HI. Although the study demonstrated glycemic improvements, it did not meet its primary endpoint because reductions in hypoglycemia events measured through finger-stick self-monitored blood glucose (SMBG) testing were not statistically significant compared with placebo. However, the company reported consistent and clinically relevant improvements across multiple continuous glucose monitoring (CGM)-based hypoglycemia endpoints in both treatment arms. The sunRIZE open-label extension (OLE) phase is ongoing, with Rezolute reporting a high participation rate and several indicators of improved glycemic control. These include a notable reduction in the use of background standard-of-care therapies.

Financial Position and Funding

Rezolute reported US$90.0 million in cash, cash equivalents, and marketable securities at the end of September 2026. This compared with US$107.8 million at the end of the previous fiscal quarter. During Q1, the company recorded US$12.8 million in R&D expenses and US$6.6 million in G&A expenses, contributing to a net loss of US$18.5 million. 

On November 5, 2026, Rezolute also filed a US$400 million shelf registration statement with the U.S. Securities and Exchange Commission (SEC). The registration covers potential future offerings of debt securities, common stock, preferred stock, warrants, subscription rights, purchase contracts, depositary shares, and units.  The shelf registration provides the company with flexibility to offer securities periodically following the registration statement's effectiveness. It does not represent US$400 million in cash already raised or immediately available funding. Specific offering amounts and terms will be established in subsequent prospectus supplements.

The combination of its existing cash position and potential access to capital markets provides financial flexibility as Rezolute advances its late-stage clinical programs and prepares for potential regulatory submissions.

Hyperinsulinism and Refractory Hypoglycemia Demand Treatment

Hyperinsulinism is a disorder characterized by excessive insulin secretion or activity, resulting in abnormally low blood glucose levels. Congenital HI is an important cause of persistent hypoglycemia in infants and children and can lead to neurological injury when glucose levels are not promptly restored and maintained. According to the International Guidelines for the Diagnosis and Management of Hyperinsulinism, HI is the most common and severe cause of persistent hypoglycemia in infants and children. The guidelines identify diazoxide as the first-line pharmacological treatment for established HI, while somatostatin analogues may be used as second-line therapies in patients who do not respond to diazoxide or cannot tolerate it.

On November 6, 2026, Yun Zhong of Wedbush reiterated a "Buy" rating and US$6 price target.

Some patients with focal disease may benefit from surgery, while pancreatic surgery may be required in certain cases of diffuse HI. The guidelines also highlight the limited availability of treatment options and the potential for hypoglycemia-related neurological complications. They identify the need for additional medical therapies that could reduce reliance on existing treatments and the need for pancreatectomy.

Tumor-induced hyperinsulinism represents another source of refractory hypoglycemia. Non-islet-cell tumor hypoglycemia (NICTH) can occur when tumors produce excessive amounts of insulin-like growth factor 2, which activates insulin receptors and produces insulin-like metabolic effects. This can result in severe hypoglycemia, particularly in patients with advanced or unresectable tumors. A clinical review published in the Journal of Clinical Endocrinology and Metabolism describes NICTH as "a rare but serious paraneoplastic condition." Complete surgical removal of the underlying tumor can resolve the associated hypoglycemia, but surgery may be delayed or infeasible in patients with extensive tumor burden or metastatic disease. Other management approaches include increased caloric intake, intravenous glucose or dextrose, glucocorticoids, and, in selected cases, growth hormone, or continuous glucagon infusion.

'Buy' Ratings All Around

On November 5, 2026, Chen Lin of What Is Chen Buying? What Is Chen Selling? weighed in on the company, writing, "RZLT, phase 3 data in December, one month from now. I am very confident it would be positive. They already had 7 out of 8 and only need 9 out of 16. Again, this is a very different setting from last year's trial. It is an open-label setup. There were hedge funds going from hospital to hospital to check on patients (only 8 total in question). The rumors that I am hearing are likely positive."

Recent analyst coverage for Rezolute includes:

• On November 6, 2026, Yun Zhong of Wedbush reiterated a "Buy" rating and US$6 price target.
• On November 6, 2026, Albert Lowe of Craig-Hallum reiterated a "Buy" rating and raised the price target from US$7 to US$10.
• On November 5, 2026, Julian Harrison of BTIG reiterated a "Buy" rating and a US$6 price target.
• On October 16, 2026, Jason McCarthy of Maxim Group reiterated a "Buy" rating and a US$14 price target.
• On October 15, 2026, Douglas Tsao of H.C. Wainwright & Co. reiterated a "Buy" rating and US$10 price target.
• On October 6, 2026, Jason Butler of Citizens JMP reiterated a "Buy" rating and raised the price target from US$11 to US$15.
• On October 6, 2026, Daniel Brims of Lake Street reiterated a "Buy" rating and raised the price target from US$9 to US$12. 
• On October 5, 2026, Pete Stavropoulos of Cantor Fitzgerald assigned a "Buy" rating.

Regulatory and Commercial Outlook Among Catalysts

Rezolute is advancing ersodetug across two late-stage clinical programs targeting different forms of hyperinsulinism. Management highlighted a potential US$5 billion combined market opportunity across the company's HI indications and outlined plans to submit a BLA for ersodetug for one or potentially both indications in 2027. The timing of potential submissions will depend on the clinical and regulatory progress of each program.

The upLIFT topline results expected in December 2026 represent an upcoming clinical milestone for the tumor HI program, while the congenital HI pathway will depend on further FDA interactions and review of the sunRIZE clinical data.

Common Questions From Investors

What is the status of Rezolute's Phase 3 upLIFT study?

Enrollment is complete in the study, which enrolled up to 16 hospitalized participants with tumor HI. Topline results are expected by mid-December 2026. Seven of the first eight participants met the primary endpoint responder criterion and discontinued intravenous glucose.

What did the FDA recommend for Rezolute's congenital HI program?

Following its review of additional clinical data, the FDA recommended that Rezolute request a Type B pre-BLA meeting as a precursor to a potential BLA submission for congenital HI. The FDA has not determined whether ersodetug is approvable, and additional clinical studies may still be required.

Why is the sunRIZE study important?

The Phase 3 sunRIZE study evaluated ersodetug in congenital HI. Although it missed its primary endpoint based on finger-stick blood glucose measurements, the company reported clinically relevant improvements across multiple CGM-based hypoglycemia endpoints. Its open-label extension is ongoing. 

What is Rezolute's current financial position?

The company reported US$90.0 million in cash, cash equivalents, and marketable securities as of September 30, 2026. It also filed a US$400 million shelf registration statement on November 5, 2026, providing potential access to additional capital through future securities offerings. 

What is the potential market opportunity for ersodetug?

Management cited a potential US$5 billion combined market opportunity across the company's HI indications during its October 29, 2026, Guggenheim Healthcare Spotlight Series Q&A. This figure represents management's estimate rather than an independently verified market valuation. 

What are the next major catalysts for Rezolute?

The next major milestones include:

• Mid-December 2026: Expected topline results from the Phase 3 upLIFT study.
• 2027: Potential BLA submission for ersodetug in tumor HI, congenital HI, or both indications.
• Ongoing: Further clinical and regulatory progress from the sunRIZE open-label extension and FDA interactions.